Injection Advancement
Hanmi Pharmaceutical is to use the latest injection device in the development of a new persistent diabetes medicine called the Quantum Project.
The company announced on July 27 that it recently signed a comprehensive master agreement with the Ypsomed Group, the global leader of injection systems in Switzerland, for pen systems and auto-injectors.
The device will be applied to the Quantum Project, which are three new drugs to treat diabetes using the company’s Lapscovery platform. Based on this, Hanmi Pharmaceutical plans to prepare for the development of full-scale commercialization.
The Quantum Project consists of three treatments: a once-monthly treatment of "efpeglenatide," which is a GLP-1 family drug, “LAPS Insulin 115,” which is under development as a once-weekly insulin formulation, and “LAPS Insulin Combo,” the combination of “LAPSInsulin115” and “efpeglenatide.”
Ulrike Bauer, vice president of the sales and marketing division of the Ypsomed Group, said, “We are happy to sign an agreement with Hanmi Pharmaceutical to supply pen systems and auto-injectors. The group will make efforts to become the ideal partner to advance the commercialization of the Quantum Project, which has high market potential.”
Hanmi Pharmaceutical CEO Lee Gwan-sun Lee said, “We are happy to sign a partnership contract with the Ypsomed Group, the global leader in drug injection systems, to commercialize the Quantum Project. With the contract, the company will provide patients worldwide with the best therapy using the most user-friendly injection systems.”